3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
Thoracic
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Thyroid Cancer, Papillary
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Trastuzumab
2
trametinib
1
tipifarnib
1
sargramostim
1
entrectinib
1
dabrafenib
1
cobimetinib
1
alectinib
1
aldesleukin
1
Vemurafenib
1
Taxes
1
Ritonavir
1
Radiotherapy
1
Paclitaxel
1
Nivolumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Indinavir
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Cancer, Papillary
×
entrectinib
×
Gynecologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA